Brinker Capital Investments LLC Acquires 7,882 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Brinker Capital Investments LLC boosted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating) by 27.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,460 shares of the company’s stock after purchasing an additional 7,882 shares during the quarter. Brinker Capital Investments LLC’s holdings in Castle Biosciences were worth $951,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wasatch Advisors Inc. grew its holdings in Castle Biosciences by 10.5% during the 1st quarter. Wasatch Advisors Inc. now owns 3,443,847 shares of the company’s stock valued at $154,491,000 after buying an additional 327,359 shares in the last quarter. Vanguard Group Inc. grew its holdings in Castle Biosciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,176,227 shares of the company’s stock valued at $52,766,000 after buying an additional 13,386 shares in the last quarter. Invesco Ltd. grew its holdings in Castle Biosciences by 2.8% during the 1st quarter. Invesco Ltd. now owns 1,079,032 shares of the company’s stock valued at $48,405,000 after buying an additional 29,372 shares in the last quarter. Millennium Management LLC grew its holdings in Castle Biosciences by 230.9% during the 2nd quarter. Millennium Management LLC now owns 902,089 shares of the company’s stock valued at $19,801,000 after buying an additional 629,448 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its holdings in Castle Biosciences by 44.4% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 641,512 shares of the company’s stock valued at $14,081,000 after buying an additional 197,170 shares in the last quarter. Institutional investors own 82.43% of the company’s stock.

Castle Biosciences Stock Performance

Shares of Castle Biosciences stock opened at $26.64 on Monday. The stock has a market cap of $702.02 million, a price-to-earnings ratio of -13.00 and a beta of 1.00. The stock has a 50 day moving average price of $23.50 and a 200-day moving average price of $25.58. Castle Biosciences, Inc. has a one year low of $15.58 and a one year high of $48.40.

Castle Biosciences (NASDAQ:CSTLGet Rating) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.07). Castle Biosciences had a negative return on equity of 11.87% and a negative net margin of 42.79%. The company had revenue of $37.01 million during the quarter, compared to analysts’ expectations of $34.36 million. Sell-side analysts predict that Castle Biosciences, Inc. will post -2.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on CSTL. Robert W. Baird cut their price target on Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating for the company in a report on Thursday, November 3rd. Scotiabank began coverage on Castle Biosciences in a report on Wednesday, January 4th. They set a “sector outperform” rating and a $54.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences currently has a consensus rating of “Buy” and a consensus price target of $57.14.

Insider Activity at Castle Biosciences

In related news, insider Derek J. Maetzold sold 3,833 shares of the business’s stock in a transaction on Monday, December 5th. The stock was sold at an average price of $24.79, for a total transaction of $95,020.07. Following the completion of the transaction, the insider now owns 294,723 shares in the company, valued at approximately $7,306,183.17. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Derek J. Maetzold sold 3,833 shares of the business’s stock in a transaction on Monday, December 5th. The stock was sold at an average price of $24.79, for a total transaction of $95,020.07. Following the completion of the transaction, the insider now owns 294,723 shares in the company, valued at approximately $7,306,183.17. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Bradbury sold 7,704 shares of the business’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $22.89, for a total value of $176,344.56. Following the transaction, the director now owns 199,539 shares of the company’s stock, valued at approximately $4,567,447.71. The disclosure for this sale can be found here. Insiders sold a total of 22,072 shares of company stock worth $507,358 in the last quarter. 7.30% of the stock is owned by company insiders.

Castle Biosciences Profile

(Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Recommended Stories

Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating).

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.